top of page
LEARN HOW WE APPROACH
REGENERATIVE CARDIAC MEDICINE OF TOMORROW
Innovative Approach
BREAKTHROUGH THERAPIES BY ACTIVATING REGENERATION & HEALING
RECARDIO (REgenerative CARDIOvascular Therapy) is a late clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe.
The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardia tissue after an injury.
PRESS
Aiming to improve the body’s repair mechanisms by harnessing its own regenerative capacity, Recardio has now proceeded with the clinical evaluation of its lead candidate dutogliptin in cardiovascular indications to the global pivotal Phase 3 study. Other development programs are in earlier clinical and preclinical stage.
CLINICAL
CLINICAL STUDIES
PARTNERING
WHY CHOOSE RECARDIO
RECARDIO’s therapeutic approach represents multiple product leads in the field of cardiology - more than the company can develop on its own.
​
To ensure optimal clinical development and success, RECARDIO is stepping up its collaboration activities and has already initiated joint development with interested pharmaceutical leaders in the field.
​
RECARDIO offers an exciting partnering and collaboration opportunity for experienced global investment groups and players in cardiac health.
bottom of page